In March 2025, Celgene announced a study is to compare the effectiveness and safety of golcadomide in combination with ...

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T entering Phase 3 ...

had said that the agency is ready to review mRNA vaccines, on a similar basis to CAR-T treatments. The necessity for the agency to clarify that it is ready to review the potential products ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus ...

mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T). In January 2025, Cartesian announced that it has received written agreement from the FDA under the SPA process on the overall ...

"If I was a manufacturer of car tires and they ... outright ban the use of mRNA-based vaccines for 10 years is being ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...